Her current research focus is in cancer pharmacogenetics (the relationship between genetics, drug response and/or drug toxicity). Her work in breast cancer pharmacogenetics investigates the development of biomarkers to predict for toxicity and response for chemotherapy and hormone therapy. She is Chief Investigator of the national pharmacogenetics study PGSNPS and also pharmacogenetics lead on several UK breast cancer studies. She has established research collaborations throughout the UK, USA, Japan and the Netherlands.